U.S. markets open in 7 hours 27 minutes
  • S&P Futures

    3,827.75
    -11.25 (-0.29%)
     
  • Dow Futures

    31,474.00
    +9.00 (+0.03%)
     
  • Nasdaq Futures

    12,533.50
    -130.25 (-1.03%)
     
  • Russell 2000 Futures

    2,191.70
    +2.00 (+0.09%)
     
  • Crude Oil

    67.12
    +1.03 (+1.56%)
     
  • Gold

    1,702.30
    +3.80 (+0.22%)
     
  • Silver

    25.51
    +0.22 (+0.88%)
     
  • EUR/USD

    1.1901
    -0.0024 (-0.20%)
     
  • 10-Yr Bond

    1.5540
    0.0000 (0.00%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3817
    -0.0011 (-0.08%)
     
  • USD/JPY

    108.4400
    +0.0580 (+0.05%)
     
  • BTC-USD

    50,320.80
    +948.53 (+1.92%)
     
  • CMC Crypto 200

    1,018.46
    +75.29 (+7.98%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,743.25
    -121.07 (-0.42%)
     

ResMed Inc (RMD) Files 10-K for the Fiscal Year Ended on June 30, 2020

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
GuruFocus.com
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ResMed Inc (NYSE:RMD)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on June 30, 2020. ResMed Inc is a part of the healthcare sector. It develops and distributes medical products for treating and diagnosing respiratory disorders. ResMed Inc has a market cap of $25.68 billion; its shares were traded at around $177.51 with a P/E ratio of 41.57 and P/S ratio of 8.74. The dividend yield of ResMed Inc stocks is 0.88%. ResMed Inc had annual average EBITDA growth of 10.20% over the past ten years. GuruFocus rated ResMed Inc the business predictability rank of 5-star. GuruFocus has detected 1 severe warning sign with ResMed Inc. .


For the last quarter ResMed Inc reported a revenue of $770.3 million, compared with the revenue of $705.0 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $3 billion, an increase of 13.4% from last year. For the complete 30-year financial data, please go here.. For the last five years ResMed Inc had an average revenue growth rate of 12.1% a year.

The reported diluted earnings per share was $4.27 for the year, an increase of 52.5% from previous year. Over the last five years ResMed Inc had an EPS growth rate of 8.9% a year. The ResMed Inc enjoyed an operating margin of 27.36%, compared with the operating margin of 24.4% a year before. The 10-year historical median operating margin of ResMed Inc is 23.82%. The profitability rank of the company is 9 (out of 10).

At the end of the fiscal year, ResMed Inc has the cash and cash equivalents of $463.2 million, compared with $147.1 million in the previous year. The long term debt was $1.3 billion, compared with $1.3 billion in the previous year. The interest coverage to the debt is 7.4. ResMed Inc has a financial strength rank of 7 (out of 10).

At the current stock price of $177.51, ResMed Inc is traded at 79.3% premium to its historical median P/S valuation band of $99.00. The P/S ratio of the stock is 8.74, while the historical median P/S ratio is 4.73. The intrinsic value of the stock is $60.98 a share, according to GuruFocus DCF Calculator. The stock gained 32.65% during the past 12 months.

Directors and Officers Recent Trades:

  • President, Sleep Business James Hollingshead sold 2,400 shares of RMD stock on 08/03/2020 at the average price of $202.02. The price of the stock has decreased by 12.13% since.

  • President, SaaS Business Rajwant Sodhi sold 1,500 shares of RMD stock on 08/03/2020 at the average price of $200.06. The price of the stock has decreased by 11.27% since.

  • Chief Administrative Officer David Pendarvis sold 5,919 shares of RMD stock on 08/03/2020 at the average price of $201.99. The price of the stock has decreased by 12.12% since.

For the complete 20-year historical financial data of RMD, click here.

This article first appeared on GuruFocus.